Financials
Financial year 2025
PHARMA NORD from Zaventem, company number BE0459551554, closed financial year 2025 with a result of € 77,582 after tax. For that financial year PHARMA NORD recorded a gross margin of € 2.4 million and equity of € 20,513. Compared with financial year 2024, the result moved from € 81,060 to € 77,582. The company is profitable. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.
€ 20,513
▼ 11% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 77,582
▼ 4% vs 2024
Profit after tax over the fiscal year.
€ 91,828
▲ € 85,895 vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 80,000 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
20.6
▲ 1.8 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 2.1 million
▲ 23% vs 2024
€ 101,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 411,087
▲ 97% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 1.1 million
▼ 4% vs 2024
Loans from banks and other lenders, long and short.
€ 257,594
▲ 6% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 333,501
▲ 19% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 1,740,447 | € 2,072,768 | € 1,956,545 | € 2,403,259 | ▲ 23% |
| Profit after taxes | € 44,024 | € 140,884 | € 81,060 | € 77,582 | ▼ 4% |
| Equity | € 97,357 | € 138,241 | € 22,930 | € 20,513 | ▼ 11% |
| Total debts | € 1,511,858 | € 1,606,499 | € 1,848,766 | € 1,751,218 | ▼ 5% |
| Cash | € 418,906 | € 141,964 | € 5,933 | € 91,828 | ▲ € 85,895 |
| Retained profit | € 78,765 | € 119,649 | € 4,338 | € 1,921 | ▼ 56% |
| Dividend | € 0 | € 100,000 | € 196,371 | € 80,000 | ▼ 59% |
| Bank debt | € 0 | € 0 | € 1,128,858 | € 1,080,124 | ▼ 4% |
| Balance sheet total | € 1,609,215 | € 1,744,741 | € 1,871,696 | € 1,771,731 | ▼ 5% |
| Employees (FTE) | 18.3 | 19.2 | 18.8 | 20.6 | ▲ 1.8 |
Key figures of PHARMA NORD, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMA NORD?
What happened at PHARMA NORD in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 77,582 (▼ 4% vs 2024). Source: NBB ↗
- New establishment in Zaventem. KBO
- Start of the company according to the CBE. KBO
- ELI WALLIN became a director. NBB
In short
From € 44,024 profit in 2022 to € 77,582 profit in 2025.
Paid € 216,971 in corporate taxes since 2022.
Best year ever: 2023, with € 140,884 profit.
On average € 116,700 of value added per employee in 2025.
A new publication or filing at PHARMA NORD? We notify you, reason included.
Follow PHARMA NORDDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
ELI WALLIN
Director
since 1996
Establishments
Establishment units
Physical locations of this company
Minervastraat 14
1930 Zaventem
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0459.551.554
- VAT number
- BE 0459.551.554
- Registered office
- Minervastraat 14, 1930 Zaventem
- Names & denominations
- PHARMA NORD
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 23 December 1996
- Peppol
- Active · Active since 8 Jan 2026
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van public relations en communicatie
Public relationsbureaus
Activiteiten van reclamebureaus
Publiciteitsagentschappen
Adviesbureaus op het gebied van public relations en communicatie